3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma
Authors:
- G.K. Abou AlfaGAG.K. Abou Alfa
- P. JohnsonPJP. Johnson
- J. KnoxJKJ. Knox
- J. LacavaJLJ. Lacava
- T. LeungTLT. Leung
- A. MoriAMA. Mori
- M.A. LeberreMLM.A. Leberre
- D. VoliotisDVD. Voliotis
- L. SaltzLSL. Saltz
- 1 September 2007
- journal article
- abstracts
- Published by Elsevier in European Journal of Cancer Supplements
- Vol. 5 (4) , 259